newsfilter
← Latest News
Business Wire·

New Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA® (teprotumumab-trbw) to Support Thyroid Eye Disease (TED) Patient Outcomes

-- Additional data presented at ATA 2023 include a subgroup analysis from the TEPEZZA Phase 4 clinical trial and insights on the impact of TED on quality of life (QOL) -- Horizon Therapeutics plc (NASDAQ:HZNP) today